Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avila Therapeutics has entered into a non-clinical evaluation agreement to use the National Institute of Allergy and Infectious Diseases’ (NIAID’s) preclinical services program to evaluate its HCV protease (NS3) inhibitor.
Subscribe to our email newsletter
AVL-192 is an oral compound that silences the HCV protease (NS3) through irreversible covalent bonding to the target protein.
Preclinical data presented by Avila demonstrated that it selectively inhibits drug-resistant mutations of HCV protease.
NIAID-funded contractors are conducting preclinical studies of AVL-192 to help enable its future clinical development, and Avila retains exclusive rights to this compound, as part of an agreement.
Avila CSO Juswinder Singh said NS3 protease as a target of therapeutic intervention in HCV infection and the ability of AVL-192 to strike at known drug-resistant mutations will be a feature of next generation protease inhibitors.